Jacc: Cardiooncology最新文献

{"title":"Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia: A Prospective Study.","authors":"Yu Kang, Benedicte Lefebvre, Amanda Smith, Daniel Koropeckyj-Cox, Priya Brahmbhatt, Bonnie Ky, Joseph Carver, Shannon McCurdy, Selina Luger, Marielle Scherrer-Crosbie","doi":"10.1016/j.jaccao.2025.11.004","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.11.004","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reduced Exercise Capacity in Breast Cancer Compared to HFpEF: Mechanistic Insights From Invasive Exercise Testing.","authors":"Isabela Landsteiner, Stephen J Foulkes, Joseph Campain, Carly E Camphausen, Daniel A Zlotoff, Gregory D Lewis, Mark J Haykowsky","doi":"10.1016/j.jaccao.2025.12.002","DOIUrl":"https://doi.org/10.1016/j.jaccao.2025.12.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":" ","pages":""},"PeriodicalIF":12.8,"publicationDate":"2026-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145991262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Evaluation of the Cardiovascular Effects of BRAF and MEK Inhibitors in Patients With Melanoma","authors":"Claire Glen MBChB ,&nbsp;Stephen J.H. Dobbin MBChB, PhD ,&nbsp;Kenneth Mangion MD, PhD ,&nbsp;Alasdair Henderson PhD ,&nbsp;Katriona Brooksbank PhD ,&nbsp;Caroline J. Coats MBChB, PhD ,&nbsp;Frederick H. Epstein PhD ,&nbsp;Peter Kellman PhD ,&nbsp;Elaine Butler ,&nbsp;Thomas R. Jeffry Evans MBChB ,&nbsp;Rob Jones MBChB, PhD ,&nbsp;John McClure PhD ,&nbsp;Giles Roditi MBChB ,&nbsp;Yun Yi Tan MBChB ,&nbsp;Ashita Waterston MBChB, PhD ,&nbsp;Paul Welsh PhD ,&nbsp;Mark C. Petrie MBChB ,&nbsp;Ninian N. Lang MBChB, PhD","doi":"10.1016/j.jaccao.2025.08.006","DOIUrl":"10.1016/j.jaccao.2025.08.006","url":null,"abstract":"<div><h3>Background</h3><div>Rapidly accelerated fibrosarcoma B-type (BRAF) and MEK inhibitors have revolutionized outcomes for patients with BRAF-mutated melanoma. However, they are associated with cardiovascular adverse effects. The real-world incidence and risk factors for these effects are poorly described.</div></div><div><h3>Objectives</h3><div>The aim of this study was to characterize the incidence and risk factors for BRAF inhibitor– and MEK inhibitor–associated hypertension and cancer therapy–related cardiac dysfunction (CTRCD) in a real-world setting.</div></div><div><h3>Methods</h3><div>A prospective, longitudinal, cohort study was undertaken among patients with melanoma treated with BRAF and MEK inhibitors in a regional cancer network (March 2021 to March 2023). Baseline cardiotoxicity risk stratification was assessed using the European Society of Cardiology cardio-oncology guideline–recommended tool. Comprehensive cardiovascular assessment was performed at baseline and at 4, 12, and 24 weeks, including home and clinic blood pressure, echocardiography, stress perfusion cardiovascular magnetic resonance imaging and blood biomarkers. CTRCD was defined using International Cardio-Oncology Society definitions.</div></div><div><h3>Results</h3><div>A total of 61 participants were enrolled. Twenty-eight participants (45.9%) developed hypertension and 45.9% developed CTRCD: 24 (85.7%) mild, 3 (10.7%) moderate, and 1 (3.6%) severe. All moderate or severe CTRCD was evident by 4 weeks and at least partially reversible. No patient at low baseline risk developed moderate or severe CTRCD. Patients with CTRCD had higher median baseline N-terminal pro–B-type natriuretic peptide compared with those without (109 pg/mL [Q1-Q3: 51-380 pg/mL] vs 54 pg/mL [Q1-Q3: 29-149 pg/mL]; <em>P</em> = 0.047). There were no robust associations between hypertension nor cardiovascular magnetic resonance imaging–derived myocardial or perfusion characteristics and incident CTRCD.</div></div><div><h3>Conclusions</h3><div>BRAF inhibitor– and MEK inhibitor–associated hypertension and CTRCD are common. The present results reinforce the utility of baseline cardiotoxicity risk stratification, including assessment of N-terminal pro–B-type natriuretic peptide. Future guidelines should consider recommending early surveillance echocardiography for higher risk patients.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 852-866"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145253234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Biomarkers and Cardiotoxicity in Breast Cancer","authors":"Alan H. Baik MD","doi":"10.1016/j.jaccao.2025.10.003","DOIUrl":"10.1016/j.jaccao.2025.10.003","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 886-889"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145753876","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pretreatment Circulating Vascular Biomarkers Predict Cancer Therapy–Related Cardiac Dysfunction During HER2+ Breast Cancer Treatment","authors":"Dakota Gustafson PhD ,&nbsp;Priya Mistry MSc ,&nbsp;Crizza Ching BSc ,&nbsp;Inbar Nardi-Agmon MD ,&nbsp;Christopher Yu MD, PhD ,&nbsp;Chun-Po Steve Fan PhD ,&nbsp;Christian Houbois MD ,&nbsp;Eitan Amir MD, PhD ,&nbsp;Thomas Marwick MBBS, PhD, MPH ,&nbsp;Husam Abdel-Qadir MD ,&nbsp;Chris McIntosh PhD ,&nbsp;Paaladinesh Thavendiranathan MD, SM ,&nbsp;Jason E. Fish PhD","doi":"10.1016/j.jaccao.2025.09.004","DOIUrl":"10.1016/j.jaccao.2025.09.004","url":null,"abstract":"<div><h3>Background</h3><div>Blood biomarkers to predict cancer therapy–related cardiac dysfunction (CTRCD) risk remain limited.</div></div><div><h3>Objectives</h3><div>The aim of this study was to identify circulating biomarkers associated with CTRCD risk in HER2⁺ breast cancer patients.</div></div><div><h3>Methods</h3><div>In the discovery cohort, women with early-stage HER2⁺ breast cancer receiving anthracycline and trastuzumab therapy underwent serial evaluation with cardiac magnetic resonance imaging (CMR), echocardiography, clinical assessments, and blood biobanking every 3 months. Multiomics profiling of 3 circulating cardiac damage biomarkers and 35 markers of inflammation, angiogenesis and endothelial activation and profiling of &gt;2,000 plasma microRNAs were performed before and early during treatment (3 and 6 months). CTRCD was defined by left ventricular ejection fraction measured on CMR, and sensitivity analyses used echocardiography. Pretreatment protein biomarkers were measured in a validation cohort.</div></div><div><h3>Results</h3><div>Among 136 women, 37 (27.2%) developed CMR-defined CTRCD within 15 months. The endothelial activation markers angiopoietin-2, endothelin-1, and endoglin were elevated before and during treatment, while sE-selectin was elevated during treatment in patients who developed CTRCD. Inflammatory biomarkers (myeloperoxidase, interferon-gamma–induced protein-10, and interferon-α) were significantly higher before treatment in patients who developed CTRCD. No differences were observed in cardiac injury biomarkers (troponin I, B-type natriuretic peptide, and growth differentiation factor-15). Pretreatment plasma microRNAs revealed distinct CTRCD-associated signatures. Integrating pretreatment clinical variables, CMR parameters, and biomarkers into a single random forest model, angiopoietin-2, myeloperoxidase, and endoglin were identified as the strongest predictors of CTRCD, findings that were subsequently validated in a cohort of 38 HER2⁺ breast cancer patients.</div></div><div><h3>Conclusions</h3><div>Pretreatment endothelial-centric and inflammatory biomarkers outperformed both clinical and CMR measures in predicting CTRCD during chemotherapy.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 870-885"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145753875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tight Regulation of Erk Activity Protects From Anthracycline-Induced Cardiotoxicity","authors":"Benedetta Coppe PhD ,&nbsp;Nadia Mercader PhD","doi":"10.1016/j.jaccao.2025.10.002","DOIUrl":"10.1016/j.jaccao.2025.10.002","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 849-851"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145753874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inhibition, But Not Depletion, of Erk Signaling Ameliorates Anthracycline-Induced Cardiotoxicity in Zebrafish","authors":"Maryam Moossavi PhD ,&nbsp;Ping Zhu PhD ,&nbsp;Yonghe Ding PhD ,&nbsp;David Mondaca-Ruff PharmD, PhD ,&nbsp;Feixiang Yan PhD ,&nbsp;Xueling Ma MD ,&nbsp;Xiaolei Xu PhD","doi":"10.1016/j.jaccao.2025.08.005","DOIUrl":"10.1016/j.jaccao.2025.08.005","url":null,"abstract":"<div><h3>Background</h3><div>Anthracycline-induced cardiotoxicity (AIC) is a unique type of cardiomyopathy that limits the clinical use of anthracyclines in cancer therapy. Although several cardiomyopathy-related pathways have been identified, including extracellular signal–regulated kinase (ERK) signaling, pathway-specific interventions for AIC remain unclear.</div></div><div><h3>Objectives</h3><div>The aim of this study was to investigate the role of Erk signaling in AIC using zebrafish genetics.</div></div><div><h3>Methods</h3><div>A zebrafish model of AIC was used to screen genes in known cardiomyopathy pathways, including Erk signaling. Heterozygous and homozygous mutants were evaluated for their modifying effects on AIC. In parallel, pharmacologic studies with ERK inhibitors were conducted to assess dose-dependent therapeutic effects of Erk inhibition.</div></div><div><h3>Results</h3><div><em>mek1</em>^+/− and <em>erk1</em>^+/− mutants conferred protective effects in adult zebrafish with AIC. Consistent with this, Erk phosphorylation was aberrantly elevated in AIC hearts. Although heterozygous mutants mitigated AIC phenotypes, homozygous <em>erk1</em>^−/− mutants caused cardiac dysfunction and worsened AIC. Similarly, pharmacologic inhibition of Erk with temuterkib was therapeutic at low doses but induced dose-dependent cardiotoxicity. Mechanistically, the AIC model exhibited accelerated cardiac senescence, which can be attenuated by Erk inhibition.</div></div><div><h3>Conclusions</h3><div>Aberrant Erk activation contributes to AIC, and controlled Erk inhibition may offer therapeutic benefit, potentially via antiaging mechanisms. However, optimization is essential, as excessive inhibition can be cardiotoxic.</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 833-848"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145214193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behaviorally Designed Gamification and Physical Activity Among Breast and Prostate Cancer Survivors","authors":"Alexander C. Fanaroff MD, MHS ,&nbsp;Jennifer A. Orr MSPH ,&nbsp;Chinyere Anucha BA ,&nbsp;Emily Kim BS ,&nbsp;Charles Rareshide MS ,&nbsp;Jingsan Zhu MS, MBA ,&nbsp;Meagan Echevarria MPH ,&nbsp;Stephanie Rodarte BS ,&nbsp;Mareen Kassabian BA ,&nbsp;Elina Balasian BS ,&nbsp;Bonnie Ky MD, MSCE ,&nbsp;Kevin G. Volpp MD, PhD ,&nbsp;Saro H. Armenian DO, MPH","doi":"10.1016/j.jaccao.2025.10.001","DOIUrl":"10.1016/j.jaccao.2025.10.001","url":null,"abstract":"<div><h3>Background</h3><div>Black and Hispanic cancer survivors exposed to cardiotoxic therapies are at higher risk for cardiovascular events than non-Hispanic White survivors, attributed to greater cardiovascular risk factors and lower physical activity.</div></div><div><h3>Objectives</h3><div>This study sought to determine the effect of a remotely delivered and behaviorally designed gamification intervention vs attention control on physical activity in Black and Hispanic cancer survivors with cardiovascular risk factors.</div></div><div><h3>Methods</h3><div>Between May 2022 and February 2025, Black and Hispanic breast and prostate cancer survivors who had received cardiotoxic cancer therapy and had ≥1 cardiovascular risk factor were enrolled in a randomized clinical trial with a 24-week intervention and 12-week postintervention period. Participants received a wearable device to track daily steps, established a baseline, selected a step goal increase, and were assigned to attention control (n = 76) or gamification (n = 74). The primary outcome was change in mean daily steps from baseline through the intervention period.</div></div><div><h3>Results</h3><div>Mean participant age was 64 years; 81% women, 64% Black, and 35% Hispanic. Gamification arm participants had a greater change from baseline in mean daily steps than control participants during the intervention period (+759; 95% CI: 209-1,309; <em>P =</em> 0.007) and follow-up (+581; 95% CI: −47 to 1,208; <em>P =</em> 0.070), and a greater increase in weekly minutes of moderate-vigorous physical activity during intervention (+16; 95% CI: 4-29; <em>P =</em> 0.010) and follow-up (+11; 95% CI: 0-22; <em>P =</em> 0.048).</div></div><div><h3>Conclusions</h3><div>Gamification increased physical activity compared with attention control in Black and Hispanic cancer survivors, and represents a scalable intervention to reduce cardiovascular risk in this high-risk population (RCT of Strategies to Augment Physical Activity in Black and Hispanic Breast and Prostate Cancer Survivors [ALLSTAR]; <span><span>NCT05176756</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 816-828"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining the Name of the Game in Exercise Oncology","authors":"Enat Arega MD, MSc ,&nbsp;Christina M. Dieli-Conwright PhD, MPH ,&nbsp;Eric H. Yang MD","doi":"10.1016/j.jaccao.2025.11.001","DOIUrl":"10.1016/j.jaccao.2025.11.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 829-832"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145753873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Imaging Immune Checkpoint Inhibitor Myocarditis","authors":"Edward Doris BMBS ,&nbsp;Charlotte Manisty MBBS, PhD ,&nbsp;Sivatharshini Ramalingam MBBS ,&nbsp;Gary J.R. Cook MBBS, MSc, MD ,&nbsp;Alexander R. Lyon BM, BCh, PhD ,&nbsp;Muhummad Sohaib Nazir MBBS, PhD","doi":"10.1016/j.jaccao.2025.08.001","DOIUrl":"10.1016/j.jaccao.2025.08.001","url":null,"abstract":"","PeriodicalId":48499,"journal":{"name":"Jacc: Cardiooncology","volume":"7 7","pages":"Pages 894-897"},"PeriodicalIF":12.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145041920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}